This Is MS Multiple Sclerosis Community: Knowledge & Support

Welcome to the world's leading forum on Multiple Sclerosis research, support, and knowledge. For over 10 years, This is MS has provided an unbiased community dedicated to Multiple Sclerosis patients, caregivers, and affected loved ones.
It is currently Thu May 23, 2013 2:17 pm

View unanswered posts | View active topics


Board index » Multiple Sclerosis » Drug Pipeline

All times are UTC - 8 hours [ DST ]



Post new topic Reply to topic  Page 1 of 1
  [ 7 posts ] 
  Print view Previous topic | Next topic 
Author Message
scoobyjude
 Post subject: Pleneva
PostPosted: Fri Jan 22, 2010 9:28 pm 
Offline
Family Elder
User avatar

Joined: Sat Feb 18, 2006 4:00 pm
Posts: 516
Location: suburb of Chicago, IL USA
BTG Commences Phase IIa Study Of Pleneva For Multiple Sclerosis - Quick Facts
1/21/2010 2:51 AM ET


(RTTNews) - BTG Plc (BGC.L: News ) said it commenced dosing in a European multicentre Phase IIa study of Pleneva, a novel orally administered compound under development as a potential treatment for multiple sclerosis.

According to the company, the study, in 166 patients with the relapsing-remitting form of the disease, comprises an initial 24 week double-blind, placebo-controlled dosing period followed by a 24 week open-label extension. The primary endpoint of the study is a reduction in the number of new T1 gadolinium enhanced lesions on MRI at weeks 12, 16, 20 and 24 when compared to placebo.

_________________
Dxed Jan 2006. Sx since 2002. Rebif since March 2006. "When one door closes, another opens but we often look so long and so regretfully upon the closed door that we do not see the one which has opened for us." Alexander Graham Bell
Top
 Profile  
 
CureOrBust
 Post subject:
PostPosted: Sat Jan 23, 2010 4:23 am 
Offline
Family Elder
User avatar

Joined: Wed Jul 27, 2005 3:00 pm
Posts: 2692
Location: Sydney, Australia
http://www.btgplc.com/DevelopmentPipeline/233/PlenevaBGC200134.html
Quote:
In a small single-centre, double-blind, placebo-controlled clinical pilot study, an experimental Pleneva™ prototype provided clinical benefits to patients with RRMS, including decreases in both relapse rate and EDSS scores, with additional benefits seen on pain and cognitive endpoints.
Now I'm interested.
Top
 Profile  
 
scorpion
 Post subject:
PostPosted: Sat Jan 23, 2010 6:01 am 
Offline
Family Elder
User avatar

Joined: Wed Nov 05, 2008 4:00 pm
Posts: 1323
The reduction in EDSS score got my attention as well!!! Nice find scoobyjude.
Top
 Profile  
 
dignan
 Post subject:
PostPosted: Sat Jan 23, 2010 11:25 am 
Offline
Family Elder
User avatar

Joined: Wed Aug 11, 2004 3:00 pm
Posts: 1610
Thanks for the update scooby. I've got it in the pipeline under its old, less catchy name, BGC20-0134.
Top
 Profile  
 
Suchislife
 Post subject:
PostPosted: Tue Apr 26, 2011 1:41 pm 
Offline
Getting to Know You...
User avatar

Joined: Mon Apr 25, 2011 3:00 pm
Posts: 10
Location: Havelock, NC
Do we know if this drug made it or not??? Is it in another phase?? I can see it has been awhile, but I am interested. I'm searching through the forum, but I can't seem to find it... Help if you can.
Thanks!

_________________
"If a man does not keep pace with his companions, perhaps it is because he marches to the beat of a different drummer. Let every man keep step to the music that he hears, however measured or far away." - Henry David Thoreau ~Audrey
Top
 Profile  
 
arabia
 Post subject: Re: Pleneva
PostPosted: Thu Apr 19, 2012 11:12 am 
Offline
Newbie
User avatar

Joined: Sun Mar 13, 2011 4:00 pm
Posts: 8
scoobyjude wrote:
BTG Commences Phase IIa Study Of Pleneva For Multiple Sclerosis - Quick Facts
1/21/2010 2:51 AM ET


(RTTNews) - BTG Plc (BGC.L: News ) said it commenced dosing in a European multicentre Phase IIa study of Pleneva, a novel orally administered compound under development as a potential treatment for multiple sclerosis.

According to the company, the study, in 166 patients with the relapsing-remitting form of the disease, comprises an initial 24 week double-blind, placebo-controlled dosing period followed by a 24 week open-label extension. The primary endpoint of the study is a reduction in the number of new T1 gadolinium enhanced lesions on MRI at weeks 12, 16, 20 and 24 when compared to placebo.


any update ? please
Top
 Profile  
 
DougL
 Post subject: Re: Pleneva
PostPosted: Thu Apr 19, 2012 11:20 am 
Offline
Family Elder
User avatar

Joined: Mon Jul 11, 2011 3:00 pm
Posts: 298
arabia wrote:
any update ? please

from the manufacturers web site

BGC20-0134 (Pleneva™) did not meet its primary or secondary endpoints in a six-month double-blind placebo-controlled Phase IIa study in patients with relapsing remitting multiple sclerosis. Data from approximately 65% of patients who have completed an optional six-month open-label study extension will be analysed to determine if any treatment effects are evident at 12 months that were not found after 6 months.
Top
 Profile  
 
Display posts from previous:  Sort by  
Post new topic Reply to topic  Page 1 of 1
  [ 7 posts ] 

Board index » Multiple Sclerosis » Drug Pipeline

All times are UTC - 8 hours [ DST ]

Who is online

Users browsing this forum: No registered users

You cannot post new topics in this forum
You cannot reply to topics in this forum
You cannot edit your posts in this forum
You cannot delete your posts in this forum

Search for:
Jump to: